Results 61 to 70 of about 20,748 (167)
Cancer Medicine, Volume 15, Issue 3, March 2026.ABSTRACT Background Unpaid caregiving is a critical but often under‐recognised component of the cancer care continuum. As cancer prevalence rises globally, particularly in lower‐income countries, quantifying the time and economic burden of unpaid caregiving across regions is essential for health resource planning, economic participation and support ...
Lan Gao +6 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 629-640, March 2026.Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich +5 more
wiley +1 more source
Revista Brasileira de Hematologia e Hemoterapia, 2014 Objective: The aim of this work was to demonstrate a possible relationship between anti-latency-associated peptide human latent transforming growth factor beta 1 (latent TGF-β1) expression in megakaryocytes and microvascular density in bone marrow ...
Cesar Cilento Ponce +3 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 669-677, March 2026.Knowledge of the glomerular filtration rate (GFR) is mandatory when dosing renally eliminated drugs such as vancomycin. In clinical practice, different biomarkers and various equations are used to estimate GFR (eGFR), resulting in varying estimates.
Eva‐Maria A. Wansing +7 more
wiley +1 more source
HemaSphere, Volume 10, Issue 3, March 2026.Abstract Response to cytoreductive therapy according to CALR mutation type, CALR variant allele frequency (VAF), and additional mutations has not been previously studied in essential thrombocythemia (ET). The impact of the molecular profile on treatment response and the main clinical outcomes was analyzed in 557 CALR ET patients (CALR Type 1, n = 339 ...
Marta Santaliestra +28 more
wiley +1 more source
Single-cell analysis based dissection of clonality in myelofibrosis
Nature Communications, 2020 Myelofibrosis is a myeloproliferative neoplasm. Here, the authors show the clonal evolution of myelofibrosis during JAK inhibitor therapy, revealing how the treatment results in an increase in clonal complexity and a gain of RAS pathway mutations.
Elena Mylonas +21 more
doaj +1 more source
What's Your Diagnosis? A Case of Extreme Thrombocytosis in a Dog
Veterinary Clinical Pathology, EarlyView.
Stephanie F. Anderson +5 more
wiley +1 more source
Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies
Haematologica, 2016 Bone marrow fibrosis is a central pathological feature and World Health Organization major diagnostic criterion of myelofibrosis. Although bone marrow fibrosis is seen in a variety of malignant and non-malignant disease states, the deposition of ...
Abdallah Abou Zahr +7 more
doaj +1 more source
Journal of Clinical Laboratory Analysis, Volume 40, Issue 6, March 2026.The PrimerDesign Quasa kit demonstrates efficacy as a reliable assay for the detection of JAK2V617F mutation, exhibiting potential for quantitative analysis when samples are analysed in duplicate. This assay validation information may prove valuable to laboratories seeking to implement a simplified JAK2V617F mutational test. ABSTRACT Introduction Janus
Deborah Vaz +2 more
wiley +1 more source
Organoids for Metabolic Disease Modeling
Journal of Inherited Metabolic Disease, Volume 49, Issue 2, March 2026.ABSTRACT Inherited metabolic diseases (IMDs) are a diverse group of rare genetic disorders that disrupt metabolic pathways, leading to severe clinical manifestations. Disease models ranging from complex animal models to simple in vitro systems have provided insights into IMDs, but each has limitations.
Arif Ibrahim Ardisasmita +2 more
wiley +1 more source